Replies to post #28647 on NorthWest Biotherapeutics Inc (NWBO)

[sd_investor_22]

The paper "Incidence of Early Pseudo-progression in a Cohort
of Malignant Glioma Patients Treated With
Chemoirradiation With Temozolomide"

has a Kaplan-Meier survival curve with numbers for each.

n=18 for Real-early -progression
n=18 for pseudo early-progression
n=49 for no early progression

21% pseudo

From the paper

"The Diagnosis and Treatment of Pseudoprogression, Radiation
Necrosis and Brain Tumor Recurrence", Int. J. Mol. Sci. 2014, 15, 11832-11846;

They say

The incidence of pseudoprogression has not been reported in a large series of
studies, and there is a highly variable rate in the small case studies examined. Depending on the
response criteria used and period examined, the reported incidence varies from 5.5% to 31% [24].

So...5.5% to 31% would be a range.

So I assume you are looking at there being anywhere from 3 to 17 in the group, as an estimate. That is a big range, and again, this is why this group is not in the study and it really needs to be looked at in total after awhile as the numbers play out.